title: Inhibition of IL-17A in atherosclerosis.
abstract: OBJECTIVE
  To determine the effects of interleukin (IL)-17A inhibition on experimental atherosclerosis.
  
  
  RESULTS
  ApoE(-/-) mice were treated with either rat anti-mouse IL-17A, mouse anti-mouse IL-17A or isotype-matched control antibodies for 12 weeks (n=8-10 per group). Ldlr(-/-) mice were transplanted with IL-17A-deficient or wild type bone marrow (n=8 per group). Rat anti-mouse IL-17A treatment obviously reduced plaque size by 43% (p<0.01) without evidence of reduced IL-17A signaling. In contrast, mouse anti-mouse IL-17A treatment and IL-17A deficiency in bone marrow cells did not alter lesion size despite significant reduction of IL-17A production.
  
  
  CONCLUSIONS
  Inhibition of IL-17A signaling does not alter lesion development in Th1-biased C57BL/6 ApoE(-/-) and Ldlr(-/-) mice with already low levels of IL-17A production. Alteration of lesion development after repeated injections of rat anti-mouse IL-17A antibody in ApoE(-/-) mice could not be attributed to blockade of IL-17A signaling.
authors.affiliation: Laboratory of Cardiovascular Immunology, Institute of Cardiology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430022, China.
authors.forename: Xiang
authors.initials: X
authors.lastname: Cheng
authors.forename: Soraya
authors.initials: S
authors.lastname: Taleb
authors.forename: Jun
authors.initials: J
authors.lastname: Wang
authors.forename: Ting-Ting
authors.initials: TT
authors.lastname: Tang
authors.forename: Jian
authors.initials: J
authors.lastname: Chen
authors.forename: Xing-Li
authors.initials: XL
authors.lastname: Gao
authors.forename: Rui
authors.initials: R
authors.lastname: Yao
authors.forename: Jiang-Jiao
authors.initials: JJ
authors.lastname: Xie
authors.forename: Xian
authors.initials: X
authors.lastname: Yu
authors.forename: Ni
authors.initials: N
authors.lastname: Xia
authors.forename: Xin-Xin
authors.initials: XX
authors.lastname: Yan
authors.forename: Shao-Fang
authors.initials: SF
authors.lastname: Nie
authors.forename: Meng-Yang
authors.initials: MY
authors.lastname: Liao
authors.forename: Yan
authors.initials: Y
authors.lastname: Cheng
authors.forename: Ziad
authors.initials: Z
authors.lastname: Mallat
authors.forename: Yu-Hua
authors.initials: YH
authors.lastname: Liao
mesh_terms: D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D001057:Apolipoproteins E / Q000172:deficiency; D050197:Atherosclerosis / Q000276:immunology* / Q000517:prevention & control; D005260:Female; D020381:Interleukin-17 / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000502:physiology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D058226:Plaque, Atherosclerotic / Q000517:prevention & control; D051381:Rats; D011973:Receptors, LDL / Q000172:deficiency; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000906:Antibodies; D001057:Apolipoproteins E; D020381:Interleukin-17; D011973:Receptors, LDL